| Literature DB >> 26465878 |
Shazia Hosein1, Alhelí Rodríguez-Cortés2, Damer P Blake1, Karin Allenspach3, Jordi Alberola2, Laia Solano-Gallego4.
Abstract
Canine leishmaniosis (CanL) due to Leishmania infantum is a chronic zoonotic systemic disease resulting from complex interactions between protozoa and the canine immune system. Toll-like receptors (TLRs) are essential components of the innate immune system and facilitate the early detection of many infections. However, the role of TLRs in CanL remains unknown and information describing TLR transcription during infection is extremely scarce. The aim of this research project was to investigate the impact of L. infantum infection on canine TLR transcription using a susceptible model. The objectives of this study were to evaluate transcription of TLRs 2, 3, 4 and 9 by means of quantitative reverse transcription polymerase chain reaction (qRT-PCR) in skin, spleen, lymph node and liver in the presence or absence of experimental L. infantum infection in Beagle dogs. These findings were compared with clinical and serological data, parasite densities in infected tissues and transcription of IL-17, IL-22 and FoxP3 in different tissues in non-infected dogs (n = 10), and at six months (n = 24) and 15 months (n = 7) post infection. Results revealed significant down regulation of transcription with disease progression in lymph node samples for TLR3, TLR4, TLR9, IL-17, IL-22 and FoxP3. In spleen samples, significant down regulation of transcription was seen in TLR4 and IL-22 when both infected groups were compared with controls. In liver samples, down regulation of transcription was evident with disease progression for IL-22. In the skin, upregulation was seen only for TLR9 and FoxP3 in the early stages of infection. Subtle changes or down regulation in TLR transcription, Th17 cytokines and FoxP3 are indicative of the silent establishment of infection that Leishmania is renowned for. These observations provide new insights about TLR transcription, Th17 cytokines and Foxp3 in the liver, spleen, lymph node and skin in CanL and highlight possible markers of disease susceptibility in this model.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26465878 PMCID: PMC4605763 DOI: 10.1371/journal.pone.0140325
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primer sequences for selected reference genes.
| Gene name (abbreviation) | Primer sequence 5’– 3’ | Product size (base pairs) | Anneal. temp (°C) | GenBank accession number | Tissues employed | Reference |
|---|---|---|---|---|---|---|
|
| F: CACTGGGAAAACAATGCAGA | 123 | 56 | AY_283372 | Liver | [ |
| R: ACAAAGTCAGGTTTATAGCCAACA | Lymph node | |||||
| Spleen | ||||||
|
| F: TCACCATCGGAGCCATCT | 112 | 57 | XM_546491 | Liver | [ |
| R: GTTCCCACCACGCTCTTCT | Lymph node | |||||
|
| F: ACGGAAAGGAGATGAAAGCA | 99 | 56 | XM_535458 | Lymph node | [ |
| R: CCTGCTCATTGGGAGTGAA | Spleen | |||||
|
| F: GCCTTGGATCTCTTGATGGA | 92 | 56 | XM_535807 | Liver | [ |
| R: TTCTTGGCTCTTATGCGATG | Skin | |||||
|
| F: GGAGAAAGCTGCCAAATATG | 193 | 55 | NM_001003142 | Spleen | [ |
| R: ACCAGGAAATGAGCTTGACA | Skin | |||||
|
| F: GGCTTTGAAGATGGCATTGT | 127 | 56 | XM_850340 | Skin | [ |
| R: CACCCTCCACCTCTGGAATA |
Primer sequences for target genes of interest.
| Target gene(abbreviation) | Primer sequence 5’– 3’ | Product size (base pairs) | Annealing temp (°C) | GenBank accession number | Reference |
|---|---|---|---|---|---|
|
| F: AGTGGCCAGAAAAGCTGAAA | 263 | 54.3 | NM_001005264 | [ |
| R: ATCCAGTTGCTCCTTCGAGA | |||||
|
| F:GTCCAATTTCATTAAGGCCAAG | 129 | 54 | XM_540020.2 | This study |
| R:TGTCACTTGCTCAGTCTCCTTT | |||||
|
| F: CAGCATTCCAGTTTGAAGCA | 140 | 54.3 | AB080363 | This study |
| R: AAGACTTCGAGGCTGACCAA | |||||
|
| F: GCCTGGAGTACCTGCTCTTG | 128 | 55 | NM_001002998.1 | This study |
| R: GTTACGGGCATGGTCACAG | |||||
|
| F: CCGATCTACCTCACCTTGGA | 166 | 60 | NM_001165878.1 | [ |
| R: TCGCAGAACCAGGATCTCTT | |||||
|
| F: TCCAGCAGCCCTATATCACC | 254 | 60 | XM_538274.2 | [ |
| R: TTGGCTTAGCTTGTTGCTGA | |||||
|
| F: GGCTCCTGCTGTATCGTAGC | 179 | 55 | NM_001168461.1 | This study |
| R: CGCATGTTGTGGAATTTGAA |
Median (range) and p-values for the parasite densities in infected tissues (parasites per mg/tissue) in both infected groups.
| Tissue | Group 1 (6 months post infection) | Group 2 (15 months post infection) | Group 1 vs Group 2 |
|---|---|---|---|
|
| 21005.95 (0–110083.30) | 2365.10 (17.10–39808.00) |
|
|
| 29450.70 (60.90–140482) | 10668.30 (37.50–73515.10) | p = 0.199 |
|
| 897.55 (0–22410.10) | 1595 (16.60–5774.20) | p = 0.695 |
|
| 95.85 (1.60–2455.10) | 1651.70 (3.50–47616.80) |
|
(*) shows significant differences (p = <0.05).
Median (range) and p-values for the transcription of target genes within liver samples.
| Genes (Liver) | Controls | Group 1 (6 months post infection) | Group 2 (15 months post infection) | Controls vs Group 1 | Controls vs Group 2 | Group 1 vs Group 2 |
|---|---|---|---|---|---|---|
|
| 96.58 (84.42–1392.73) | 550.77 (128.43–903.51) | 366.63 (201.42–892.36) |
|
| p = 0.764 |
|
| 239.34 (159.73–3256.20) | 298.42 (95.98–831.85) | 214.97 (103.31–288.47) | p = 0.809 | p = 0.962 | p = 0.695 |
|
| 162.66 (118.09–2348.42) | 203.00 (47.76–400.73) | 132.04 (90.40–303.30) | p = 0.148 | p = 0.315 | p = 0.417 |
|
| 556.32 (336.05–7636.49) | 1387.00 (192.72–7405.74) | 497.47 (149.37–956.36) | p = 0.196 | p = 0.109 | p = 0.502 |
|
| 0.58 (0.27–6.98) | 0.49 (0.08–1.99) | 1.80 (1.63–17.4) | p = 0.377 | p = 0.571 | p = 0.060 |
|
| 6.63 (3.36–76.40) | 0.46 (0.12–5.73) | 2.83 (2.10–5.05) |
| p = 0.033 |
|
|
| 2.25 (2.05–32.54) | 3.59 (0.81–11.61) | 2.04 (1.35–36.79) | p = 0.480 | p = 0.232 | p = 0.563 |
Significant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*) p-value<0.016.
Median (range) and p-values for the transcription of target genes within lymph node samples.
| Genes (Lymph node) | Controls | Group 1 (6 months post infection) | Group 2 (15 months post infection) | Controls vs Group 1 | Controls vs Group 2 | Group 1 vs Group 2 |
|---|---|---|---|---|---|---|
|
| 1221.20 (591.02–2049.55) | 567.61 (266.89–4039.30) | 1148.49 (946.55–1644.48) |
| p = 0.740 |
|
|
| 2287.15 (1091.26–5313.42) | 310.27 (136.98–2233.89) | 146.77 (100.96–202.02) |
|
|
|
|
| 1838.31 (1212.52–3401.61) | 349.76 (130.66–1490.22) | 284.16 (230.33–388.74) |
|
| p = 0.872 |
|
| 1565.95 (987.70–3183.26) | 2012.24 (665.90–7213.90) | 651.89 (341.12–943.30) | p = 0.287 |
|
|
|
| 19.38 (0–55.43) | 3.45 (0–22.95) | 5.96 (0.71–7.01) |
|
| p = 0.729 |
|
| 67.88 (13.74–1440.20) | 4.95 (1.18–352.62) | 1.87 (0.92–3.35) |
|
|
|
|
| 1029.74 (324.94–2005.54) | 197.26 (45.63–1248.18) | 35.05 (20.14–55.11) |
|
|
|
Significant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
Median (range) and p-values for the transcription of target genes within spleen samples.
| Genes(Spleen) | Controls | Group 1 (6 months post infection) | Group 2 (15 months post infection) | Controls vs Group1 | Controls vs Group 2 | Group 1 vs Group 2 |
|---|---|---|---|---|---|---|
|
| 3007.40 (1798.94–3287.07) | 2383.58 (1550.86–4654.14) | 2544.15 (1568.13–5424.72) | p = 0.118 | p = 0.417 | p = 0.627 |
|
| 1028.55 (517.35–2312.03) | 741.91 (157.04–2191.08) | 367.96 (147.59–1120.88) | p = 0.515 | p = 0.088 | p = 0.085 |
|
| 3765.41 (2733.20–4570.21) | 1157.07 (483.38–2924.33) | 920.75 (445.67–1293.38) |
|
| p = 0.182 |
|
| 980.30 (560.20–1222.08) | 6866.13 (778.07–119451.01) | 2316.45 (395.51–26120.09) |
| p = 0.364 | p = 0.167 |
|
| 1.46 (0.53–6.57) | 2.27 (0.66–12.49) | 1.84 (1.05–3.19) | p = 0.393 | p = 0.905 | p = 0.273 |
|
| 17.67 (11.68–35.42) | 4.33 (0.94–22.27) | 3.04 (0.18–20.26) |
|
| p = 0.661 |
|
| 43.73 (20.67–85.44) | 62.78 (7.51–210.02) | 39.94 (18.33–101.60) | p = 0.222 | p = 0.758 | p = 0.139 |
Significant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
Median (range) and p-values for the transcription of target genes within skin samples.
| Genes (Skin) | Controls | Group 1 (6 months post infection) | Group 2 (15 months post infection) | Controls vs Group 1 | Controls vs Group 2 | Group 1 vs Group 2 |
|---|---|---|---|---|---|---|
|
| 67.93 (35.42–100.44) | 201.43 (107.29–316.82) | 130.71 (129.19–198.86) | p = 0.042 | p = 0.171 | p = 0.462 |
|
| 277.62 (155.65–399.59) | 351.49(99.57–802.59) | 125.43 (60.34–125.60) | p = 0.728 | p = 0.257 | p = 0.038 |
|
| 157.39 (120.51–194.28) | 172.54 (118.81–267.37) | 103.71 (102.90–323.95) | p = 0.262 | p = 0.762 | p = 0.940 |
|
| 307.64 (214.71–400.57) | 1152.08 (509.62–1625.92) | 174.57 (73.13–229.63) |
| p = 1.000 | p = 0.044 |
|
| 0.43 (0.23–0.64) | 0.98 (0.31–9.06) | 2.70 (0.98–4.12) | p = 0.218 | p = 0.200 | p = 0.282 |
|
| 9.57(2.15–16.99) | 5.01 (1.91–9.02) | 2.51 (0.28–5.92) | p = 0.924 | p = 0.171 | p = 0.093 |
|
| 1.07 (0.82–1.33) | 11.06 (1.53–21.54) | 6.50 (1.73–8.93) |
|
| p = 0.550 |
Significant Bonferroni corrected p-values are highlighted bold (p< = α/3).
(*)p-value<0.016.
(^) indicates marginal significance.
Fig 1Heat maps illustrating the positive (red) and negative (blue) correlation values between parasite densities at six months post infection (a) and fifteen months post infection (b) in liver, lymph node, spleen and skin with transcription from genes of interest, serological parameters and clinical scores.
Fig 2Heat maps illustrating the positive (red) and negative (blue) correlation values between clinical score at six months post infection (a) and fifteen months post infection (b) in liver, lymph node, spleen and skin with transcription from genes of interest, serological parameters and parasite densities.